Fig. 1: Compound screening for enhancers of Kcc2 expression in primary cortical neurons yields Kenpaullone. | Nature Communications

Fig. 1: Compound screening for enhancers of Kcc2 expression in primary cortical neurons yields Kenpaullone.

From: Repurposing cancer drugs identifies kenpaullone which ameliorates pathologic pain in preclinical models via normalization of inhibitory neurotransmission

Fig. 1

Screening paradigm using three rounds of primary screen based on luciferase (LUC) activity followed by secondary screen including Kcc2 RT-qPCR and clomeleon chloride imaging. Bottom panel: Four compound “winners” including Kenpaullone (KP); screening conducted in primary mouse neurons.

Back to article page